Business
Aussie cannabis players blaze a trail in Europe – The Australian Financial Review
ASX-listed MGC Pharma has floated in London while Little Green Pharma has placed $22 million of shares, as the high-potential European market beckons.
Australia is so set up to have a really great crack at being the dominant player in Europe, said LGP founder and CEO Fleta Solomon.
She said the Australian advantage was that the Therapeutic Goods Associations good manufacturing practice (GMP) standards were recognised as complying with the European Unions high bar, whereas producers in other countries had to negotiate EU clearance.
The biggest companies in the world dont have EU GMP. Thats what is so exciting for us as Australian players. Our GMP…
-
Noosa News21 hours agoE-bikes shouldn’t be banned. The illegal ones are already illegal
-
General18 hours agoChina was the big disruptor in our region. Now the US is determined to take that title
-
General18 hours agoSpaceX to invest $3 billion in Musk’s xAI startup
-
General22 hours agoAlgal bloom ‘disaster’ prompts royal commission call as impact spreads to mussel farms